A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

PHASE2CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

August 31, 2018

Conditions
Ankylosing Spondylitis
Interventions
OTHER

Placebo

DRUG

Bimekizumab

Bimekizumab in different dosages.

Trial Locations (74)

16635

As0008 001, Duncansville

33180

As0008 005, Aventura

34239

As0008 030, Sarasota

36207

As0008 019, Anniston

75231

As0008 006, Dallas

77030

As0008 018, Houston

78731

As0008 020, Austin

91786

As0008 009, Upland

92037

As0008 007, La Jolla

97239

As0008 014, Portland

98122

As0008 002, Seattle

32174-11

As0008 022, Ormond Beach

02111

As0008 027, Boston

07728

As0008 021, Freehold

44109-19

As0008 015, Cleveland

Unknown

As0008 156, Dobrich

As0008 151, Plovdiv

As0008 154, Plovdiv

As0008 155, Plovdiv

As0008 150, Rousse

As0008 101, Québec

As0008 100, Victoria

As0008 103, Winnipeg

As0008 205, Brno

As0008 206, Hustopeče

As0008 207, Olomouc

As0008 208, Pardubice

As0008 201, Prague

As0008 202, Prague

As0008 209, Prague

As0008 210, Prague

As0008 211, Prague

As0008 203, Zlín

As0008 302, Cologne

As0008 304, Hamburg

As0008 308, Hanover

As0008 303, Herne

As0008 301, Ratingen

As0008 400, Budapest

As0008 403, Budapest

As0008 402, Debrecen

As0008 401, Veszprém

As0008 466, Bydgoszcz

As0008 453, Elblag

As0008 456, Elblag

As0008 455, Krakow

As0008 461, Lublin

As0008 467, Nowa Sól

As0008 451, Poznan

As0008 462, Poznan

As0008 450, Torun

As0008 454, Warsaw

As0008 459, Warsaw

As0008 457, Wroclaw

As0008 460, Wroclaw

As0008 465, Wroclaw

As0008 601, Moscow

As0008 604, Moscow

As0008 605, Moscow

As0008 607, Moscow

As0008 600, Saint Petersburg

As0008 606, Saint Petersburg

As0008 608, Saint Petersburg

As0008 609, Saint Petersburg

As0008 610, Saint Petersburg

As0008 801, A Coruña

As0008 800, Córdoba

As0008 803, Santiago de Compostela

As0008 700, Kiev

As0008 707, Kyiv

As0008 705, Ternopil

As0008 708, Uzhhorod

As0008 706, Vinnytsia

As0008 704, Zaporizhya

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT02963506 - A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter